4//SEC Filing
Koppel Adam 4
Accession 0000950170-24-004276
CIK 0001707502other
Filed
Jan 11, 7:00 PM ET
Accepted
Jan 12, 4:56 PM ET
Size
6.2 KB
Accession
0000950170-24-004276
Insider Transaction Report
Form 4
Koppel Adam
Director
Transactions
- Award
Common Stock
2024-01-11$5.53/sh+904,160$5,000,005→ 4,034,582 total(indirect: See footnotes)
Footnotes (2)
- [F1]On January 8, 2024, BCLS II Equity Opportunities, LP ("BCLS II Equity") entered into a securities purchase agreement with the Issuer pursuant to which the Issuer agreed to issue and sell 904,160 shares of Common Stock to BCLS II Equity at a price of $5.53 per share (the "January 2024 Private Placement"). The January 2024 Private Placement closed on January 11, 2024.
- [F2]Represents shares of Common Stock held by BCLS SB Investco, LP ("BCLS SB"), Bain Capital Life Sciences Fund II, L.P. ("BCLS Fund II"), BCLS II Investco, LP ("BCLS II Investco"), BCLS II Equity and BCIP Life Sciences Associates, LP ("BCIPLS" and, together with BCLS SB, BCLS Fund II, BCLS II Investco and BCLS II Equity, the "Bain Capital Life Sciences Entities"). Bain Capital Life Sciences Investors, LLC ("BCLSI") (i) is the ultimate general partner of each of BCLS SB, BCLS Fund II, BCLS II Investco and BCLS II Equity and (ii) governs the investment strategy and decision-making process with respect to investments held by BCIPLS. Dr. Koppel is a Partner of BCLSI. As a result, Dr. Koppel may be deemed to share voting and dispositive power with respect to the securities held by the Bain Capital Life Sciences Entities. Dr. Koppel disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein.
Documents
Issuer
Solid Biosciences Inc.
CIK 0001707502
Entity typeother
Related Parties
1- filerCIK 0001578965
Filing Metadata
- Form type
- 4
- Filed
- Jan 11, 7:00 PM ET
- Accepted
- Jan 12, 4:56 PM ET
- Size
- 6.2 KB